Exelixis Inc. Common Stock vs Kenvue Inc. Common Stock — how do they compare? Exelixis Inc. Common Stock trades at $60.39 (market cap $14.62B), while Kenvue Inc. Common Stock trades at $17.67 (market cap $34.06B). The key difference: Kenvue Inc. Common Stock is far larger — about 2.3× Exelixis Inc. Common Stock's market cap, and Kenvue Inc. Common Stock pays a 4.74% dividend while Exelixis Inc. Common Stock pays none. Which is the better fit depends on your goals.
| EXEL | KVUE | |
|---|---|---|
Market Cap | $14.62B | $34.06B |
Volume | 2,684,957 | 23,267,228 |
Sector | Health | Consumer Staples |
52-Week High | $59.13 | $19.83 |
52-Week Low | $34.54 | $14.11 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $13.95B | $41.56B |
Dividend Yield | — | 4.74% |
Trailing returns across standard periods
Latest headlines on both assets
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →